Recent

% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

  • terry_insm terry_insm Feb 28, 2014 9:16 AM Flag

    140 characters - half truths

    Much of what the poster wraps around the Podinhaler is true. Approved in most countries around the world
    and yes given socialized medicines seal of cost approval,Novartis has a winner,as well as a 2 year head start on Arikace.The drug will be completely entrenched when Arikace arrives in Europe and Canada. As of now there is no US Market for Arikace as Insmed has so far they do not intend to file Arikace for CF

    Do they call the registries in Europe "formularies" or is that the US?
    Has 140 seen the test results and can tell the future of the label ? No, no one has,Insmed hasn't even filed in Europe and Canada. Does 140 know the cost that Will Lewis has said Insmed must meet to be competitive?

    So the info splattered here is somewhere in between but one point is very clear. Arikace for CF is an ORPHAN which is a small market, a competitive market and Insurance companies (bakwardpalms comment this morning) would rather cover at a lower cost than care how well a patient does. Ill let the poster who has riled the crowd continue ,but until the results of NTM, most DD is yet to be defined
    Good Luck

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
INSM
11.45+0.12(+1.06%)Jul 29 4:00 PMEDT